InvestSMART

Alterity Therapeutics Limited (ASX:ATH)

ALERT: Price-sensitive ASX Announcement for ATH
Current share price for ATH : $0.590 -0.04 (-6.35%)+
Announcement
Release
9 Jul 2026 3:52PM
Price at Release
$0.630
Full Release
download
Summary
Alterity Therapeutics Limited announced the receipt of A$3.98 million from the Australian Government's R&D tax incentive for the 2025 financial year, which supports their ongoing research and development initiatives. This funding will aid in the continued development of therapies for neurodegenerative diseases, including preparations for a Phase 3 clinical trial for Multiple System Atrophy (MSA). The company's lead drug candidate, ATH434, has demonstrated promising results in Phase 2 trials. Alterity is focused on creating disease-modifying treatments for neurodegenerative conditions from its bases in Melbourne and San Francisco.
Key Points
  • Alterity Therapeutics received A$3.98 million in R&D tax incentives.
  • The funds are part of the Australian Government’s R&D tax incentive program.
  • The incentive supports development in neurodegenerative disease therapies.
  • Alterity is preparing for a Phase 3 trial in Multiple System Atrophy (MSA).
  • ATH434 has shown meaningful efficacy in Phase 2 trials for MSA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.